- Home
- WRAP vs TLSA Comparison
WRAP vs TLSA Comparison
Compare WRAP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- TLSA
- Stock Information
- Founded
- WRAP 2016
- TLSA 2013
- Country
- WRAP United States
- TLSA United Kingdom
- Employees
- WRAP N/A
- TLSA N/A
- Industry
- WRAP Ordnance And Accessories
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- TLSA Health Care
- Exchange
- WRAP Nasdaq
- TLSA Nasdaq
- Market Cap
- WRAP 82.1M
- TLSA 87.8M
- IPO Year
- WRAP N/A
- TLSA 2000
- Fundamental
- Price
- WRAP $1.62
- TLSA $0.78
- Analyst Decision
- WRAP
- TLSA
- Analyst Count
- WRAP 0
- TLSA 0
- Target Price
- WRAP N/A
- TLSA N/A
- AVG Volume (30 Days)
- WRAP 251.1K
- TLSA 347.9K
- Earning Date
- WRAP 11-14-2024
- TLSA 12-31-2024
- Dividend Yield
- WRAP N/A
- TLSA N/A
- EPS Growth
- WRAP N/A
- TLSA N/A
- EPS
- WRAP N/A
- TLSA N/A
- Revenue
- WRAP $4,231,000.00
- TLSA N/A
- Revenue This Year
- WRAP N/A
- TLSA N/A
- Revenue Next Year
- WRAP N/A
- TLSA N/A
- P/E Ratio
- WRAP N/A
- TLSA N/A
- Revenue Growth
- WRAP N/A
- TLSA N/A
- 52 Week Low
- WRAP $1.21
- TLSA $0.41
- 52 Week High
- WRAP $7.01
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- WRAP 46.24
- TLSA 33.06
- Support Level
- WRAP $1.53
- TLSA $0.73
- Resistance Level
- WRAP $1.79
- TLSA $1.07
- Average True Range (ATR)
- WRAP 0.12
- TLSA 0.09
- MACD
- WRAP -0.03
- TLSA -0.02
- Stochastic Oscillator
- WRAP 23.08
- TLSA 12.86
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.